Introduction
Epithelial and endothelial barriers separate the organisms from the external environment and the body compartments from each other. The tight intercellular seals responsible for the effective separation were identified as zonula occludens or tight junctions (TJ) by electron microscopy more than 50 years ago (for review see [1] ). In the last 25 years the discovery of the transmembrane proteins of TJs [2] and the signalling pathways regulating TJ functions [3] resulted in a great advance in understanding how epithelial and endothelial barriers work and how this knowledge can be exploited in disease therapies, drug discovery and drug targeting.
The non-invasive delivery of hydrophilic drugs or large biopharmaceuticals to the systemic circulation or to specific organs protected by a barrier, like the central nervous system (CNS), is still a big challenge. Drug absorption or penetration across epithelial and endothelial barriers is restricted by several factors. Efflux transporters expressed at high levels in epithelia [4] and the blood-brain barrier (BBB) [5] prevent not only the flux of xenobiotics, but also drug molecules to reach their target. Local metabolic barriers act as a second line of defence and specific enzymes are able to inactivate drugs, cleave proteins and peptides, or other biologically active compounds [6] . The third major cause is the presence of intercellular TJs that strictly limit the paracellular route. In the last 50 years several methods, molecules, and excipients have been investigated for the safe and reversible opening of these junctions to enhance drug absorption and penetration. Low efficacy and high toxicity prevented these approaches to be useful for pharmaceutical therapy. New TJ modulators, designed to interact directly with TJ proteins or regulating molecules, are promising candidates to improve drug delivery.
Major epithelial and endothelial barriers and drug delivery
The paracellular permeability, one of the most important determinants of drug transport, of various epithelial tissues and barriers differs greatly [7] . Transepithelial electrical resistance (TEER), measuring paracellular ion flux and reflecting the tightness of the intercellular junctional complex, is the lowest in the small intestine, which is considered as a leaky epithelial tissue. The TJs in the colon and the stomach are of intermediate tightness, while brain capillaries and the skin epithelial cells form very tight paracellular barriers.
Epithelial barriers of the gastrointestinal tract
Oral administration of drugs is the most popular and widespread method of drug therapy. The patients' compliance is high, because it is safe, efficient, easily accessible and causes minimal discomfort. Membrane permeability is one of the major factors which determine drug absorption after oral administration. The total surface area of the intestine is approximately 200 m 2 . Except for the buccal and rectal mucosa, where the surface consists of stratified squamous epithelium, a columnar epithelial cell layer covers the surface in the other parts of the gastrointestinal (GI) tract. The lower parts of the small intestine, jejunum and ileum, are considered as the major place of drug absorption, because of the leaky paracellular tight junctions reflected by the low transepithelial electrical resistance, as compared to the other parts of the GI tract [7] . The villous structure of the jejunum and ileum amplifies the surface area four and two-folds, respectively, as compared to the colon [8] , another factor in drug absorbance. Although the gastric epithelium is much tighter than the small intestine [7] , gastric absorption can be substantial for drugs administered in rapidly dissolving formulations or for lipophilic molecules [8] . The great differences in the paracellular permeability between the regions of the GI tract [8] are caused by the dissimilar anatomical structures, distinct lipid composition of the plasma membranes and expression of diverse members of the claudin TJ protein family [2] .
The paracellular permeability pathway in the buccal and rectal mucosa is restricted, and their surface area is small (approx. 100-200 cm 2 ), nevertheless they are important drug delivery sites. Due to their special anatomical location the blood from their submucosa is directly drained toward the superior or inferior vena cava, respectively, avoiding first pass metabolism in the liver and intestine, which is important for a fast effect in crisis therapy (e.g. anti-angina treatment, anticonvulsants, analgesics, antipyretics).
Airway epithelium
Drug delivery across pulmonary epithelia, ciliated epithelial cells, type I and type II pneumocytes, is an attractive route for non-invasive local and systemic therapy [9] . The alveolar surface area is large, about 160 m 2 , close to the surface area of the GI tract. Pulmonary drug delivery systems for macromolecules, peptides and proteins, like insulin, antibodies and vaccines have been developed and their applications have a great therapeutical potential [9] . Exubera, the first inhaled insulin was approved for clinical use in Europe and the United States, but marketing was stopped in 2007.
Skin
From all of the epithelial barriers the skin is the least permeable to molecules due to its special anatomical and molecular structure. The stratum corneum, the outermost layer composed of keratin-filled corneocytes in a special lipid matrix, is responsible for the extremely low permeability to water and solutes. Despite the fact, that skin represents a major barrier to drug transport, transdermal drug delivery is the most successful non-oral technology for systemic drug delivery in the pharmaceutical market [10] . Transdermal systems offer a non-invasive, slow, sustained drug delivery across an accessible and relatively large, 1-2 m 2 surface area [10] .
Blood-brain barrier
The BBB, a dynamic interface separating the brain from systemic circulation, is the major entry route for therapeutical compounds to the CNS. The estimated total length of human brain capillaries is 650 km, with a total surface area of 10 to 20 m 2 [11] . The complex tight junctions between brain endothelial cells constitute the morphological basis of the BBB [12] . The primary role of the BBB is to create ionic homeostasis for neuronal functions [13] . It also provides the CNS with nutrients and protects it from toxic insults by sophisticated transport systems [5] . The low level of paracellular flux and transendothelial vesicular trafficking result in a transport barrier for drugs which are hydrophilic and have a molecular mass bigger than 400 Da, while the presence of effective efflux transporters at the luminal membrane of brain endothelial cells limits the brain penetration of lipophil xenobiotics and drugs. The BBB prevents 98% of potential neuropharmaceuticals, especially the new peptide or protein drugs, to reach their targets in the CNS [14] . Due to these reasons the treatment of CNS diseases, including stroke, Alzheimer's disease, and brain tumours, is still unsatisfactory and improving drug delivery to the CNS is considered essential for the future success of the therapy of neurological disorders [15] .
Alternative routes for drug delivery
Besides conventional local treatments, the nasal route can be also exploited for systemic, non-invasive delivery of drugs [16] . The nasal epithelial surface area is small, about 150 cm 2 , and consists of respiratory and olfactory regions. Although the olfactory system possesses elaborate epithelial, endothelial and glial barriers expressing occludin, claudins and other TJ proteins [17] , due to its special anatomical localization it provides a direct access to the CNS by circumventing the BBB [18] . Another advantage of the nasal delivery is the rapid onset of action, which makes this route suitable for crisis treatments. An increasing number of nasal formulations are used clinically for the treatment of migraine [16] .
A new alternative route to brain across the epithelial barriers of the eye emerges, which also bypasses the BBB. Recent experimental results indicate the possibility of drug delivery to the CNS following ocular application through non-systemic routes [19, 20] .
Potential targets of TJ modulators
Tight junctions, sealing the paracellular clefts between cells of the epithelial and endothelial barriers in mammals are elaborate structures composed of integral membrane proteins (for reviews see [2, 21] ), linker or adaptor proteins connecting them to the actin cytoskeleton [22] and signalling molecules enabling the dynamic regulation of the paracellular transport [3] . Adherens junctions (AJ) are also present in both types of barriers, however differences in their localization, morphology, and molecular composition exist. While in brain endothelial cells tight and adherens junctions are intermingled [23] , in epithelial barriers AJs are situated in the apical junctional complex in basolateral direction from the TJs. Some of the junctional proteins are found in raft-like membrane microdomains in epithelial cells [24] . These compartments can play an important role in the spatial organization of TJs and probably in the regulation of epithelial paracellular permeability. Theoretically all these components listed above can be considered as potential targets of TJ modulators (Fig. 1) . Some of the junctional proteins seem to be excellent targets for safe modulation of paracellular permeability, while targeting other adhesion molecules playing a fundamental role in morphogenesis should be considered cautiously, e.g. where loss of function is strongly linked to carcinogenesis.
Transmembrane TJ proteins
Occludin, the first integral membrane TJ protein, was supposed to contribute to both the gate and fence functions [25] . Experiments with occludin-deficient cells and animals revealed morphologically unaffected TJs and no barrier dysfunction [2] . However, chronic inflammation and hyperplasia of the gastric epithelium, calcification in the brain, testicular atrophy and other histological abnormalities in the salivary gland and in the bones were observed in occludin deficient mice [26] suggesting more complex functions of occludin. Occludin internalization by caveolar endocytosis was found to be linked to barrier dysfunction in intestinal inflammation (for review see [27] ). From the accumulated data a new role for occludin as a signal transmitter in TJs regulating development, apoptosis in healthy and cancer cells, and actin cytoskeleton emerges [2] .
Tricellulin, a recently discovered TJ protein showing partial homology with occludin, is expressed uniquely at tricellular contacts of epithelial cells [28] . It also participates in the barrier function and organization of bicellular junctions. Interestingly, the only described phenotype of tricellulin gene mutation is deafness, due to the loss of the protein from tricellular junctions in cochlear and vestibular epithelial cells [29] .
Claudins form a large gene family with 24 members identified so far, which are able to determine the tissue-, charge-and sizeselectivity of the paracellular seals [2, 21] . Data from different claudin null mutant mice strains and transfection experiments indicate that claudin-1, -3, -4, -5, -8, -11, -14 and -19 contribute to the tightness of paracellular barriers [21] . Claudins are key elements in the loss of barrier function during carcinogenesis and cancer metastasis (for review see [30] ).
The paracellular ion permeability through TJs is regulated by both sealing and pore forming claudins. Claudin-4, -8, and -14 function primarily in cation barriers, while other members of the claudin family, claudin-2, -7, -10, -13, -15, -16, form paracellular pores for cations or anions [2] . They also participate in magnesium and calcium reabsorption, as revealed by the mutation of the human claudin-16 and 19 genes [31, 32] . In MDCK mammalian renal epithelial cells tight junction leakiness is conferred by expression of claudin-2 [33] .
The differential expression of claudins in tissues and cell types provide the basis for the large spectrum of the paracellular tightness of the junctional complexes in various organs [2] . The epidermal barrier is disrupted in claudin-1 deficient mice [34] , and claudin-11 plays a role in the blood-testis barrier [35] . In the GI tract claudin-2, -3, -4, -7, -8, -12 and -15 are all expressed, but the level of their expression in various intestinal segments and their subcellular localization are different [2] . Their role in the structural organization of the intestinal barrier is emphasized by a recent finding. Claudin-15 deficient mice show a megaintestine phenotype, the upper part of the small intestine is two times larger than normal in length and diameter [36] .
The presence of claudin-1, -3, -5, -12 and -18 were described in brain endothelial cells [21] . A special regulatory role for claudin-5, expressed in endothelial but not in epithelial cells, was discovered in a knock-out mice. Tracer experiments and magnetic resonance imaging revealed that in the absence of claudin-5 the BBB permeability was selectively increased for small molecules (b800 Da), but not for larger molecules [37] .
Junctional adhesion molecules (JAMs), another family of integral membrane proteins in TJs, are involved in intercellular adhesion between the cells of barriers, as well as in adhesion between barriers and blood cells [2, 22] . JAM-A, expressed in both epithelial and endothelial cells, and coxsackie and adenovirus receptor (CAR) expressed only in epithelial cells, contribute to barrier function and cell polarity in epithelial and endothelial cells, while JAM-B and -C participates in spermatogenesis [2] . In addition, JAM-A and JAM-C control transmigration of neutrophils and monocytes across endothelial and epithelial cells, another important aspect of barrier functions. Endothelial cell-selective adhesion molecule (ESAM) is expressed in vascular endothelial cells, where it colocalizes with cadherins and catenins in junctions [38] . ESAM is present at the BBB and it is enriched in the BBB genome [39] . Loss of ESAM alters angiogenesis in pathological conditions, reduces extravasation of neutrophil leukocytes and vascular endothelial growth factor (VEGF)-induced permeability in vessels [40] .
Integral membrane TJ proteins also serve as receptors for pathogenic bacteria and viruses, and they can be the targets of bacterial toxins (for review see [41] ). Claudin-1 is a co-receptor for hepatitis virus C, and claudin-4 is a receptor for Clostridium perfringens enterotoxin (CPE), while JAM-A binds reoviruses, and coxsackie and adenoviruses target CAR [2] . CPE served as a model sequence for the design of new, highly specific TJ modulator peptides [42, 43] .
Transmembrane adherens junction proteins as targets of paracellular barrier modulators
AJs, present in both epithelial and endothelial barriers initiate and stabilize cell-cell contacts and help the formation of TJs [44] . AJ proteins also participate in the regulation of barrier permeability.
Similarly to JAMs, the calcium-dependent adhesion molecules, cadherins also belong to the immunoglobulin superfamily. E-cadherin is present in all epithelial barriers, and its presence was also demonstrated in brain endothelial cells [45] . E-cadherin is important for establishing and maintaining apico-basal polarity as well as for the formation of TJs [46] . Loss of E-cadherin in the epidermis, by conditionally inactivating its gene in mice, results in perinatal death due to the inability to retain a functional epidermal water barrier [47] . Loss of E-cadherin increases TJ permeability, and alters the localization of claudin-1, -4 and ZO-1 at TJs through activation of Rac, a small GTPase of the Rho family, and protein kinase C (PKC) [47] . Histamine increases airway epithelial cell permeability by decreasing Ecadherin-based epithelial cell adhesion [48] . E-cadherin plays a basic role in morphogenesis. Embryonic stem cells isolated from Ecadherin −/− preimplantation embryos fail to differentiate into any organized structure when induced to form teratomas in mice [46] . The loss or down-regulation of E-cadherin is a key event in the process of cancer invasion and metastasis [49] . Mutations in CDH1 that compromise the adhesive function of E-cadherin have been observed in human gastric carcinoma cell lines, lobular breast cancer, and familial gastric cancer [49] . Vascular endothelial, or VE-cadherin, another member of the large cell adhesion molecule cadherin family, is highly and uniquely expressed in the endothelium of all types of vessels [50] . VE-cadherin is indispensable for the developmental organization of the vasculature, and its inactivation or truncation leads to an embryonic lethal phenotype [50] . Vasoactive and proinflammatory mediators disrupt endothelial adherens junctions, especially the association of VEcadherin with the cytoplasmic linker molecules catenins resulting in an increase in vascular permeability [51] . It has been recently identified, that VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin [52] .
The nectins form another important family of adhesion molecules in AJs [53] . These immunoglobulin-like cell adhesion molecules provide the first scaffold for AJ and TJ formation. Nectins-1, -2, -3 are expressed in epithelial, endothelial, hematopoietic and neuronal cells in adult tissues, while nectin-4 is mainly expressed during embryogenesis [54] . Nectin-4 has been identified as a new histological and serological tumour associated marker for breast cancer [55] .
Platelet-endothelial cell adhesion molecule-1 (PECAM-1) is present in endothelial and blood cells, but absent in epithelial barriers [50] . It participates in the formation of endothelial junctions and in the transmigration of leukocytes across endothelium [56] . Effective treatment of gut barrier dysfunction was achieved using monoclonal antibodies against PECAM-1 [57] . A new role for PECAM-1 is suggested at the BBB. By counteracting intercellular adhesion molecule-1 (ICAM-1)-induced activation in brain endothelial cells it can limit rearrangements of the actin cytoskeleton and maintain the integrity of brain vascular endothelium [58] .
Similarly to transmembrane TJ proteins, some of the AJ proteins can bind infectious agents. E-adherin, transiently exposed at sites of cell extrusion, is a specific target of Listeria monocytogenes adhesion and invasion by binding Internalin A, bacterial cell surface protein [59] . Nectin-1 is a cell-surface receptor for herpes simplex virus type 1 envelope glycoprotein D, and it is used for targeting attenuated, oncolytic herpes simplex virus to infect and lyse human malignancies in preclinical studies [60] .
Signalling pathways regulating TJ functions
The dynamic changes at the junctions, disintegration and reassembly of TJs, reversible changes in paracellular permeability, are regulated by signalling pathways in epithelial barriers and the BBB (for reviews see [3, 61, 62] ). The major signalling routes that participate in TJ opening with a potential to be exploited for drug delivery involve protein kinases A, C and G (PKA, PKC, PKG), Rho kinases, myosin light chain kinase (MLCK), and the mitogen activated protein kinase (MAPK) system (Fig. 1) [3, 61, 62] . The effects of certain pathways greatly differ between tissues, cell types, and models, so it is difficult to draw general conclusions.
Conventional PKC isoforms (α, β II) participate in TJ opening or disassembly [61] . [3] . Bryostatin 1, a novel anticancer agent and a non-phorbol ester stimulator of PKC transiently increases TJ permeability in epithelial cells through rapid downregulation of PKC-α [63] . While the role of PKA is controversial in TJ regulation in epithelial barriers, it is linked to barrier tightening in brain endothelial cells [3, 62] . Elevation of intracellular cyclic AMP by cyclic-AMP analogues [64] , phosphodiesterase 4 inhibitors, or by physiological regulators, like the peptide hormone adrenomedullin [65] results in increased TEER and decreased paracellular permeability [62, 66] through enhanced expression of claudin-5 at TJs [67] . Inhibitors of this pathway could increase the paracellular permeability at the BBB.
In contrast, PKG mediates BBB opening via soluble guanylate cyclase activation and elevation of cyclic GMP [3, 62, 66] . The bradykinin B2 receptor agonist Cereport acting through this pathway could effectively and reversibly open brain endothelial TJs [68] . Pathological conditions, like hypoxia, ischemia or excessive nitric oxide (NO) release, either endogenous, or from NO-donors, also activate soluble guanylate cyclase and PKG and increase BBB permeability [62, 66] .
One of the main effector mechanisms in TJ regulation is the phosphorylation of myosin light chain (MLC) by MLCK leading to the contraction of the acto-myosin belt and disassembly of TJs [61] . Cytokines, bacterial or viral pathogens, removal of extracellular Ca 2+ , as well as bile acids, used as absorption enhancers (AEs), trigger TJ opening via MLCK activation [3] . The vasoactive mediator histamine and the lysophosphatidic acid (LPA) also compromise the integrity of brain endothelial cells by MLCK activation [69] .
Mitogen activated protein kinases (MAPKs) modulate paracellular permeability of TJs by regulating the expression of several TJ proteins (for review see [3, 61] ). Three of the four groups of MAPKs, extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 isoforms participate in regulation of the barrier function. Ethanol-induced decrease in the barrier function uses all three pathways, while proinflammatory cytokines can induce both Erk1/2 and p38 MAPKs. Bile salts, reactive oxygen species (ROS), pathogenic factors of viruses and bacteria activate predominantly the Erk1/2 via Ras and Raf [3] . While all the above mentioned pathways result in a decrease in the paracellular barrier function, activation of Erk1/2 signalling pathway by negatively controlling claudin-2 expression can also enhance paracellular tightness in MDCK renal epithelial cells [33] . In contrast, Erk1/2 inhibiton by inducing claudin-2 expression in renal epithelial cells leads to a decreased TEER [33] , which is in agreement with the role of claudin-2 known to be able to form paracellular pores for cations and anions [2] . This observation indicates that regulation of paracellular barrier tightness, at least for ions, can be achieved by alteration in claudin composition within TJ complexes. Furthermore, the polymerization of claudins is critically dependent on binding to TJ membrane-associated guanylate guanylate kinase proteins ZO-1, ZO-2 and ZO-3. In Eph4 mouse epithelial cells with no expression of ZO proteins a complete lack of TJs could be observed [70] .
Activation of RhoA, Rac1 and Cdc42, members of the Rho family of GTPases, all disrupt epithelial tight junctions [71] . RhoA interacts with the PKC and MLCK pathways and regulates TJ disassembly through phosphorylation of integral membrane TJ proteins occludin and claudin-5 and scaffolding proteins ZO-1 and ZO-2 [3] . The level of RhoA is critical for TJ regulation, and either inactivation of it by C3 transferase, a specific inhibitor, or activation by cytokine interferon-γ and 2-methoxyestradiol, a microtubule destabilizing drug, leads to TJ disassembly [3] . RhoA participates in reduced brain endothelial TJ functions after LPA treatment [69] , and in ROS-induced alterations in BBB integrity and monocyte migration across brain endothelial cells [72] .
The activation of phosphoinositide 3-kinases (PI3Ks) can induce both tightening and opening of TJs depending on the inducing agent and barrier type [61] . While the PI3K/Akt pathway participates in the restitution of injured barrier in intestinal epithelium [73] , the same PI3-K/Akt signalling route is responsible for hyperpermeability induced by ROS [72, 74] , placenta-derived growth factor, VEGF [75] , HIV gp120 [76] and HIV Tat [77] in BBB models.
Lipid rafts and membrane microdomains
It is known for a long time, that lipids are involved in the formation and regulation of TJs and lipid models of the TJs have been suggested to explain lipid exchange between the apical membranes of neighbouring the cells, i.e. the "bridge" function of cell-cell adhesions ( Fig. 1 ) [78] . TJs are enriched in cholesterol [79] and alterations in cell cholesterol modulate junctional permeability for ions [80] . TJ proteins occludin, claudin-1, -3, -4, -7, JAM-A and ZO-1 have been shown to be associated with detergent insoluble glycolipid raft structures rich in caveolin-1 [24, 81] . TJ disassembly by calcium chelation resulted in displacement of TJ proteins from the lipid rafts suggesting an important role for these structures in regulation of paracellular permeability [24] . Data indicate that alteration in lipid composition of epithelial cell membrane, especially cholesterol efflux, can result in TJ modulation [81, 82] . Depletion of cholesterol from Caco2 epithelial cells by methyl-β-cyclodextrin, used as AE, results in loss of TJ integrity and displacement of occludin, claudin-3, -4, -7 and JAM-A out of the cholesterol rich membrane domains [81] . Lipid mediators and second messengers activating signalling pathways that regulate TJ permeability can mediate the effect of cholesterol depleting agents. These data suggest that TJ modulation can be achieved by changing the lipid composition of the cellular membranes or TJ-associated lipid rafts of barrier forming cells (Fig. 1 ).
Modulators acting directly on TJ components
Better understanding the molecular mechanisms that regulate the paracellular pathway led to the discovery of novel TJ modulators that directly and specifically interact with the extracellular loops of TJ proteins and the TJ-associated membrane microdomains [43, [83] [84] [85] . These peptides, enzymes or lipids can be potentially used as new excipients to safely and reversibly open TJs for delivery of hydrophilic compounds and biopharmaceuticals (Table 1 ).
Occludin
Occludin is the first TJ protein, where modulation of TJ permeability by a peptide interacting with its extracellular loop was described [86] . The 44 amino acid long OCC2 peptide (Table 2) , binding to the second extracellular domain of occludin induced a reversible increase in paracellular permeability by an increased turnover of cellular occludin in kidney epithelial cells [86] . The effect was specific, because ZO-1, ZO-2, cingulin, and E-cadherin levels and distribution were unaltered by OCC2 treatment. The same peptide also decreased TEER and depleted occludin from TJs in EpH4 mouse mammary epithelial cell line, but induced the formation of unpolarized multi-layered cell clusters [114] . Parallelly, upregulation and translocation of AJ protein β-catenin was induced, and through β-catenin/TCF/LEF activation led to the upregulation of the protooncogene c-myc [114] . Oligopeptides (9-mer and 10-mer) homologous to segments of the first external loop of occludin impaired junctional resealing on cultured epithelial cells in a reversible manner without altering ZO-1 localization [87] .
A 14 amino acid long peptide, OP [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] , corresponding to the N terminus of the first extracellular loop of occludin and containing a lipoamino acid to protect it from degradation and aggregation increased TJ permeability in Caco-2 cells treated apically [88] . The effect of OP [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] was rapid, transient, and caused no short-term toxicity. The peptide reduced TEER and increased 70 kDa dextran transport in a concentration-dependent manner in human primary airway epithelial cells [89] (Table 3) . Treatment with OP [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] peptide resulted in enhanced gene transfer efficiency of epithelial cells with adenovirus vectors due to TJ opening, increased penetration to the basolateral membrane, and greater viral binding and internalization [89] .
Organ-specific targeting of a 22 amino acid long peptide interacting with the second extracellular loop of occludin [86] (Tables 1 and 2) has been demonstrated in the blood-testis barrier in rats [90] (Tables  1-3) . A genetically engineered follicle-stimulating hormone (FSH) mutant protein which binds to Sertoli cells was used as a testisspecific carrier in the study. The occludin peptide linked to the mutant FSH induced transient and reversible disruption of the blood-testis barrier without compromising the TJ-barrier integrity in epithelia of kidney, liver, and small intestine [90] . This study indicates that targeting of peptides interacting with TJ proteins by receptor ligands may confer organ selectivity to barrier opening.
Disturbance of TJ function by directly targeting TJ proteins cannot only influence the flux of solutes, but also cellular transmigration. A cyclic occludin peptide antagonist, peptide B, containing a conserved occludin cell adhesion recognition sequence consistently and significantly increased neutrophil leukocyte migration across human umbilical vein endothelial cell layers in a time-and dose-dependent manner [108] . The increased chemotaxis correlated with disorganization of occludin, but not VE-cadherin in endothelial cells [108] .
Another approach to modify permeability is the enzymatic cleavage of TJ proteins. Der p1, a major allergen from the house dust mite Dermatophagoides pteronyssinus and a cysteine proteinase, causes cell detachment in cultured kidney and tracheal epithelial cell layers and increases the permeability of isolated sheets of bronchial mucosa [92, 150] . The time-dependent reversible disruption of TJ morphology Abbreviations: ADT-6, ADT 6-mer peptide corresponding to the bulge in E-cadherin EC-1 domain; C-CPE, C-terminal peptide of Clostridium perfringens enterotoxin; HAV-6, HAV 6-mer peptide corresponding to the groove in E-cadherin EC-1 domain; OP [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] , occludin peptide 90-103; TJ, tight junction; Zot, zonula occludens toxin.
and ZO-1 redistribution from junctions to the cytoplasm were associated with cleavage of occludin [92] . The substrate of Der p1 is the first extracellular loop of human occludin, and potential cleavage sites exist in both extracellular loops of claudin-1 [92] .
Claudins
Sequence similarities between claudin-1 and -2 and the cloned receptor for Clostridium perfringens enterotoxin (CPE) causing food poisoning led to the identification of the receptor for CPE as claudin-4 [153] . CPE can also bind to claudin-3, -6, -7, -8, and -14 [154] , the majority of claudins found in the GI tract. The C-terminal fragment of CPE (C-CPE), the binding domain of the toxin, selectively removed claudin-4 from TJs and disintegrated TJ strands in MDCK epithelial cells [95] . Parallelly with the morphological changes the TJ barrier was downregulated in a time-and dose-dependent manner [95] . A peptide sequence containing the C-terminal 16 amino acids of C-CPE (Table 2 ) was found to be responsible for the interaction with the second extracellular domain of claudin-4 and the disruption of TJs [109, 110] . Treatment of Caco-2 cells with C-CPE resulted in a decrease in TEER [110] . C-CPE enhanced the absorption of 4 kDa and 10 kDa dextran (but not that of 20 and 40 kDa) in rat jejunum [42, 109, 117] . C-CPE at 0.1 mg/ml concentration was as effective absorption enhancer as sodium caprate used in 40 mg/ml concentration, while no mucosal toxicity was observed [43, 84, 117] . The absorption enhancing effect of C-CPE was observed in the jejunum, but not in colon of rats, in contrast to sodium caprate, which was effective in both regions [117] .
These findings indicate that claudin-4 can be a target of TJ modulators, like C-CPE. Other antagonists of claudin-4, including antibodies, antibody fragments, and small interfering nucleic acids may also have the potential to open epithelial TJs and to enhance paracellular transport (Table 1) [94].
Zonulin
Zonula occludens toxin (Zot) of V. cholerae (Table 2) reversibly increases intestinal permeability by interacting with a surface receptor, activating PKC-α leading to disassembly of TJs [99] . Human zonulin was identified as the endogenous mammalian analogue of Zot, sharing a conserved N-terminal sequence corresponding to the putative receptor binding site [113] . A 45 kDa glycoprotein binding Zot and zonulin was demonstrated in brain [155] , in the epithelium of the nasal region and the small intestine [101] . This correlates well with the in vivo tissue specificity of Zot, which is active only on the mucosal side of endothelial cells and epithelial cells in the nasal region, the jejunum and ileum, but not in the colon or kidney (Table 3 ) [156] . Zot and zonulin also bind β-tubulin, and this interaction can contribute to their TJ regulating action [157] .
The TJ modulator and AE effects of Zot and active fragments derived from it, ΔG and AT1002 peptides, were demonstrated on several models (Table 3) , including nasal and intestinal epithelium and cultured brain endothelial cells. Zot reversibly enhanced the intestinal permeability to insulin and immunoglobulins in rabbits [100] . Zot also induced a rapid and reversible decrease in TEER of brain endothelial monolayers and an increase in paracellular permeability for markers sucrose and inulin, and P-glycoprotein (Pgp) efflux pump ligand drugs doxorubicin and paclitaxel [158] . Zot also acts as an adjuvant for mucosal antigen delivery and induced protective immune responses to ovalbumin and tetanus toxoid through the intranasal and rectal routes [139] . The Zot fragment ΔG enhanced the oral bioavailability of hydrophobic drugs interacting with Pgp, such as cyclosporin A, ritonavir, saquinavir and acyclovir [115] . AT1002, a 6-mer synthetic peptide fragment of Zot, enhances the in vivo intestinal absorption of cyclosporin A in rats [116] , and the nasal absorption of large hydrophilic markers 4 kDa polyethylene glycol (PEG) and inulin [144] . Beside the intestinal and nasal routes, AT1002 can potentially facilitate the pulmonary delivery of therapeutic agents (Table 3 ) [103] .
Although the Zot and zonulin receptor and its signalling cascade leading to TJ opening have not been characterized fully yet, active peptide fragments of Zot seem to be promising agents to safely and effectively improve drug and vaccine delivery across mucosal barriers and the BBB.
E-cadherin
Peptides, derived from the E-cadherin EC-1 domain containing HAV amino acid sequence can inhibit E-cadherin mediated cell-cell adhesion and modulate the intercellular junctions of cell monolayers [45, 97] . The calcium-mediated cell adhesion of cultured brain endothelial cells was prevented by HAV peptide [45] . Beside HAV peptides, corresponding to the groove region of EC-1 domain, ADT sequences containing peptides of the bulge region of E-cadherin were identified, and they were also able to increase paracellular permeability in MDCK cells [97] . HAV and ADT hexapeptides (Table 2) , interfering with the homophilic binding of E-cadherin, could time and dose-dependently reduce TEER and increase the paracellular transport of mannitol across the epithelial cell layers [97] .
Other targets
In a recent paper four groups of lipids, sphingosines, alkylglucosides, oxidized lipids and ether lipids, have been identified as nontoxic and reversible TJ modulators [85] . Treatment of brochial/ tracheal epithelial tissues with individual lipids, among them 1-1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC) resulted in a rapid reduction of TEER, up to 95%, which was restored within 1 h. Lipid treatment could also increase the permeability of the barrier tissue for fluorescein isothiocyanate (FITC)-labelled 3 kDa dextran and for the 4 kDa human peptide YY3-36 [85] . No changes in TJ structural morphology were found by immunofluorescence microscopy. Although the exact mode of action of these lipid TJ modulators are not disclosed, cell membrane lipid composition and/or lipid rafts cannot be excluded as their targets.
A novel tight junction modulator peptide, PN159 (Table 2) , has been described and tested by the same group [83, 85, 145] . PN159 shows a dose-dependent reduction of TEER with a rapid onset, quick recovery of the barrier functions on removal and good cell viability and low cytotoxicity. Parallelly with the changes in TEER, PN159 enhanced the permeability for galantamine, calcitonin, human parathyroid hormone 1-34 and peptide YY3-36 on an in vitro tissue model (Table 3) [85, 145] . In a rabbit model PN159 enhanced the systemic bioavailability of human peptide YY 3-36 via intranasal administration [145] . The specific molecular target of PN159 has not been published, but the extracellular domain of an integral membrane TJ protein cannot be excluded, since the peptide was identified by phage display on EGTA-treated human brochial epithelial cells [83] . PN159 can be a safe and potent TJ modulator to enhance drug delivery by nasal and gastrointestinal routes of administration [85] . Several peptides from the PN series (Table 2 ) may have a TJ modulator effect similar to PN159 (Table 3) .
On the analogy of claudin-4 modulators, antagonists of JAMs, peptides, antibodies, and small interfering nucleic acids, may also regulate paracellular permeability of TJs [94] .
TJ modulating effects of absorption enhancers/paracellular permeability enhancers
The controlled and reversible opening of tight junctions in the biological barriers to enhance drug delivery by safe and effective AEs or paracellular permeability enhancers (PPEs) is a long time goal in pharmaceutical and biomedical research (Table 4) . However, the [151] knowledge about the molecular composition and regulation of TJs was scarce in the past. The first integral membrane protein of the TJ complex, occludin was discovered in 1993 [25] and in the last 15 years a great progress has been achieved with the discovery of new TJ, AJ and adaptor proteins and protein families, signalling molecules and pathways [3] . Because of this fact AEs and PPEs developed before the discovery of the molecular composition and function of TJs have a rather unspecific mode of action (Table 4) . Most importantly, the difference between the effective and toxic doses of these AEs is small [7] . Despite these drawbacks some of the AEs, e.g. sodium caprate (C10), are effective and clinically used in oral formulations. Some of the AEs enhancing transdermal drug delivery, like surfactants and fatty acids, are able to increase buccal permeability. However, the mode of action of AEs is dissimilar in the skin and buccal mucosa due to the different morphological and molecular structure of the two barriers [177] . Therefore, AEs might be effective in one barrier, but not in the other, and although they are able to act on several barriers, their local action can be different.
Chelators
Calcium chelators, like ethylenediamine-N,N,N′,N′-tetraacetic acid (EDTA), ethylene glycol-bis(beta-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), and 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) increase paracellular permeability through disruption of AJs and TJs via activation of PKC [159] . EDTA enhances the permeability of Caco-2 monolayers for polyethylene glycol 4000 [125] , furosemide, carboxyfluorescein [126] , and FITC-dextran without serious cytotoxicity [178] . EDTA, EGTA and BAPTA in a hypotonic buffer caused a rapid, reversible drop in TEER and facilitated gene transfer with retrovirus or adenovirus from the apical side on cultured human differentiated airway epithelial cells by opening the intercellular TJs [146] . Chelators applied to rabbit tracheal epithelia or human nasal epithelia in vivo decreased the transepithelial voltage and amiloride sensitivity, suggesting that epithelial junctions opened. Importantly, this novel formulation enhanced both retroviral-and adenoviralmediated gene transfer to rabbit tracheal epithelia in vivo [146] . Chelation of calcium to open epithelial apical junctions could allow the targeting of airway cells with progenitor capacity that are located below the surface layer to attain persistent gene transfer [146] . This study indicates the potential clinical usefulness of chelators as TJ modulators.
Fatty acids, modified fatty acids and phosphate esters
Oleic acid is one of the most popular AEs, used in transdermal drug delivery vehicles, patches, and microemulsions [179, 180] . It is known to modulate the structure of membranes. Recent data indicate, that it does not perturb significantly the structure of lipid bilayers, and its effects can be restricted to more condensed membrane structures, such as the gel phase, more characteristic to cholesterol-containing ordered domains, like lipid rafts [160] . Oleic acid decreased TEER [127, 128] and increased mannitol flux in Caco-2 cells, parallelly with disintegration of cell-cell contacts [128] (Tables 3, 4) . Oleic acid also enhanced the permeability of mannitol across cultured alveolar epithelial cells in a calcium-dependent way [152] . Beside its effect on epithelial barrier, reversible opening of the BBB was induced by oleic acid or oleic acid emulsion injected to the carotid artery in animal studies [181, 182] . The data listed above suggest that beside its effect on membrane fluidity, oleic acid can increase paracellular permeability of dermal, gastrointestinal, alveolar and blood-brain barriers [127, 128, 152, [179] [180] [181] [182] . The exact target of oleic acid is not known, but membrane microdomains or lipid rafts could be among them [160] .
Sodium caprate, a medium chain fatty acid (C10), and a constituent of milk fat, is an absorption enhancer used in clinical therapy. It enhanced the permeability of mannitol in Caco-2 monolayers by redistribution of the cytoskeleton, TJ proteins ZO-1 and occludin, and opening of TJs through phospholipase C-dependent inositol triphosphate/diacylglycerol pathways [129, 130, 183] (Table 4) . Sodium caprate also increased TJ permeability and the transport of polysucrose in rat ileum [122] , and ampicillin bioavailability after rectal administration in humans [140] . It should be noted, that reversible mucosal damage could be observed after sodium caprate exposure [140] . On another type of barrier, sodium caprate-induced TEER drop, increased mannitol and dextran permeability, adenoviral lacZ gene transfer was more effective in airway epithelial cells than the EGTAinduced changes [151] . A redistribution of claudin-1, found following C10 but not EGTA treatment, is hypothesized as a possible mechanism of gene-transfer enhancement by C10 [151] .
Palmitoyl carnitine, a long-chain (C16) fatty acid ester, greatly enhances the absorption of hydrophilic drugs across intestinal mucosa [131] , and across Caco-2 epithelial cells accompanied by a rapid and reversible drop in TEER and opening of TJs [132] (Table 3) . However, transport enhancement was accompanied by an increase in apical membrane permeability and a reduction in cell viability [184] indicating insufficient separation between efficacy and toxicity.
Surfactants
Surfactants are solubilizing excipients widely used in oral, injectable and nasal formulations [185, 186] . Anionic, non-ionic synthetic surfactants and bile salts have been extensively studied to enhance transepithelial permeability for different marker molecules, peptides and drugs (Table 3) , but their effect on TJs is less well characterized (Table 4) .
Sodium dodecyl sulfate (SDS), an anionic surfactant had an immediate effect on paracellular permeability of Caco-2 cells, the TEER dropped, intracellular calcium levels increased, and TJs separated [133, 134] . While short-term incubation of cells with SDS caused reversible enhancement of mannitol permeability, longer exposure resulted in irreversible changes and apical membrane injury and cellular toxicity [133, 134] . The toxicity of surfactants polyoxyethylene 9 lauryl ether and sodium glycocholate given at high concentration (1%) was demonstrated after administration to rat lungs, where they induced acute inflammation [187] .
Non-ionic surfactants polysorbate 20, oxyethylene ether Solulan C24 and C16 showed a concentration dependent paracellular increase in metformin transport, parallelly with TEER decrease, however, increased permeability correlated with decreased cell viability of Caco-2 cells [135] . Nonylphenol ethoxylates can also rapidly and reversibly open paracellular TJs and enhance the transport of mannitol and daunomycin, but these non-ionic surfactants also cause irreversible changes in long-term treatments [136] .
Bile salts, sodium cholate, sodium taurocholate and sodium taurodeoxycholate, which are ionic surfactants, show also a concentration-dependent effect on epithelial permeability and morphology in Caco-2 cells and human nasal epithelial cells, respectively [133, 147] . A dose dependent reduction of cell viability was also observed at higher than critical micelle concentration, but bile salts exerted less toxicity, than non-ionic surfactants Tween 80 and Poloxamer F68 [147] .
Cationic polymers
Cationic polymers, like poly-L-lysines, polyethyleneimine and chitosan, are able to induce reversible opening of TJs in epithelial cell models [137, 188, 189] . Chitosan and its derivatives are non-toxic biocompatible polymeric AEs obtained from chitin. Because of their mucoadhesive as well as AE properties these cationic polysaccharides have been extensively studied as excipients for drug delivery across dermal, gastrointestinal, nasal, and pulmonary epithelial barriers (Table 3 ) [186, [190] [191] [192] . The chitosan-induced reversible increase in TJ permeability involves the redistribution of occludin, ZO-1 and the actin-cytoskeleton [137, 170, 171] . The process is mediated by activation of PKC-α in Caco-2 cells [138, 193] . Because of their low toxicity, good water solubility, mucoadhesive properties in addition to their TJ modulator effect, chitosan derivatives are promising candidates to enhance drug delivery in clinical setting.
Cyclodextrins
Cyclodextrins (CDs) are natural cyclic oligosaccharides derived from starch and used as excipients in marketed pharmaceutical products [194] . CDs in pharmaceutical products are mainly used as complexing agents. The potential of CDs to be used as penetration enhancers for drugs has been investigated on several models [118, 141, 148, 149, 170, 194, 195] (Table 3) . Dimethyl-β-CD is a potent enhancer of nasal and intestinal absorption of heparins and insulin in vivo and in vitro [118, 141, 148, 149, 170, 195] . The dimethyl-β-CDinduced increase in the permeability for mannitol and enoxaparin was accompanied by reduction of TEER and changes in ZO-1 distribution in epithelial cells, indicating opening of TJs [149] . Dimethyl-β-CD was found to be more effective to enhance bioavailability and absorption of heparin and insulin than all other CDs tested, hydroxypropyl-β-CD, α-, β-γ-CD [141, 148, 149, 195] . This effect seems to correlate with the cholesterol depleting efficacy of CDs [172, 173, 196] (Table 4) . Beside other well characterized effects of CDs on drug complexation and unstirred water layer [194] , cholesterol depletion from epithelial cell membrane, especially from lipid rafts, and subsequent loss of TJ integrity, displacement of TJ proteins can explain the AE effect of dimethyl-β-CD [81, 82] . However, the cholesterol depleting effect of CDs also correlate with their cytotoxicity on epithelial and BBB in vitro models [172, 196, 197] .
Nitric oxide donors
NO is a regulator of epithelial TJs, and excessive levels of NO generated by activated inducible NO synthase result in epithelial barrier dysfunction in the lung, liver and gut [198] . Decreased expression and dislocation of TJ proteins occludin, ZO-1, -2 and -3 are accompanied by enhanced transport of FITC-dextran across the ileal mucosal membrane were observed [199] .
NO donor molecules, S-nitroso-N-acetyl-DL-penicillamine (SNAP), (2-hydroxy-1-methylethyl-2-nitrosohydrazino)-N-methyl-1-propanamine (NOC7), (2-hydroxy-1-(1-methylethyl)-2-nitrosohydrazino)-1-propanamine (NOC5), and N-ethyl-2-(1-ethyl-2-hydroxy-2-nitrosohydrazino)-ethanamine (NOC12) have been tested as potential AEs in epithelial barriers of the gastrointestinal tract and in the nasal mucosa [119] [120] [121] 142, [200] [201] [202] (Table 3) . SNAP enhanced the intestinal absorption of insulin, and calcitonin in rabbits and rats, and the nasal absorption of human granulocyte colony-stimulating factor in rabbits [120, 142, 201] . When compared with other AEs, like sodium glycocholate and sodium caprate, SNAP was the most effective AE in the small intestine showing excellent effectiveness at low concentration [121] . However, the exact mechanism of action is not known, and the hypothesized effect on TJs was not examined yet.
Modulation of TJs at the blood-brain barrier for drug targeting

Modulators acting on brain endothelial TJs
There are no data yet on the effect of the newly discovered epithelial TJ modulators on the BBB, except for Zot and its fragments (Table 5) . Integral membrane TJ proteins occludin, JAMs, claudin-5, AJ proteins VEcadherin and the BBB-specific cadherin-10 [233] , or AHNAK colocalizing in TJs at the BBB [234] , could be all potential targets able to modulate paracellular permeability in brain endothelial cells. C-CPE is an unlikely TJ modulator for the CNS, because its target, claudin-4 is absent at the BBB. On the other hand, lipid modulators, like PGPC may potentially open the BBB, however, no data exist on their effects on BBB models. Gap junction proteins connexin-40 and -43 are colocalized and coprecipitated with TJ proteins in brain endothelial cells [204] . Blockers of gap-junctions, 18β-glycyrrhetinic acid and oleamide, impaired the barrier function of brain endothelial cells, decreased the TEER and increased the paracellular flux of mannitol and inulin [204] . Interestingly, no change in the expression and localization of occludin, claudin-5, JAMs or ZO-1 was detected after treatment with gap-junction inhibitors. These findings indicate, that gap-junctions can participate in the barrier function at the BBB and can be targets of TJ modulators.
There are several examples of receptor-mediated activation of signalling pathways leading to transient opening of TJs at the BBB (for review see [66] ). A Zot-binding glycoprotein was purified from brain [155] , and Zot is active as a TJ modulator at the brain endothelium. It induces a reversible, concentration-dependent TEER decrease, and an increase in the paracellular transport of the permeability markers sucrose and inulin, indicating TJ opening, without short-term toxicity in cultured brain endothelial cells [158] . Zot also enhanced the transport of chemotherapeutic agents doxorubicin and paclitaxel, ligands of Pgp [158] . The Zot active fragment ΔG, given into the carotid artery of rats, increased several fold the brain penetration of sucrose, paclitaxel, and the hydrophilic methotrexate [203] (Table 5) .
Vasoactive compounds, such as histamine, bradykinin, or leukotrienes are well-known mediators of brain oedema formation and increase BBB permeability [66, 235, 236] . Blood vessels in brain tumour tissue are more sensitive to the permeability enhancing effects of these mediators, than normal BBB [236] . Structural and functional changes found in the microvasculature of brain tumours are responsible for loss of BBB integrity (see for review [237] ). Cultured glioblastoma cells and glioma-derived factors induced downregulation of the expression of occludin, claudin 1, and claudin 5, and an increase in paracellular permeability through brain endothelial cell monolayers [238] .
Cereport (RMP-7, labradimil), a 9-mer synthetic peptide analogue of bradykinin increases intracellular calcium ion and cyclic GMP levels through bradykinin B2 receptors and induces a rapid and transient elevation in the paracellular transport of 5 kDa inulin in cultured brain endothelial cells [68, 239] . Cereport opened brain endothelial TJs [240] and enhanced the CNS delivery of carboplatin, loperamide and cyclosporin-A [205] [206] [207] [208] (Table 5) . Cereport attached to liposomes facilitated Evans blue penetration to brain in rats [241] . Enhanced tumour uptake of chemotherapeutics and increased survival were found in Cereport-treated animals using rodent models of glioma and metastatic brain tumours [207, 208] . After promising preclinical trials and Phase I studies, no benefit of Cereport was found in a Phase II study in childhood high-grade and brainstem gliomas [209] . Despite the failure of Cereport to potentiate chemotherapy of brain tumours, where high level of Pgp on the tumour cells restricts the efficacy of chemotherapy, Cereport can still be useful in enhancing drug delivery across BBB [205] [206] [207] [208] 241] .
Histamine decreases TEER and increases the permeability for paracellular markers in BBB models in vitro [66] and in vivo [235] . Small dose of histamine injected to the carotid artery resulted in a selective extravasation of Evans blue and an increase in the transport of γ-aminoisobutyric acid in the brain tumour without changing BBB permeability in other regions [210, 211] . The signalling pathway involves histamine H2 receptors, NO and cyclic GMP production [242, 243] . A reversible and concentration-dependent reduction in TJ protein ZO-1 was observed in histamine-treated retinal endothelial cells, which show similar properties to BBB [244] .
Permeability enhancers and new experimental approaches
Calcium and other divalent cations are needed for the integrity of brain endothelial TJs, similarly to epithelial cells. Removal of extracellular calcium ions by chelators BAPTA and EGTA (Table 5) results in a rapid opening of TJs in brain endothelial cells, a decrease in TEER, and an increase in sucrose flux [66] . However, chelators have not been tested for drug delivery to brain in cell culture or animal studies.
Fatty acids and modified fatty acids are effective absorption enhancers in epithelial barriers, and some of them have been also tested on the BBB. Reversible opening of the BBB to Evans blue and γ-aminoisobutyric acid was observed after intracarotid artery infusion of oleic acid in rats [181] . Since oleic acid is a PKC activator, an effect on signalling pathways regulating TJs should be considered. Emulsions made from oleic acid or linoleic acid injected to carotid artery of cats increased BBB permeability in a reversible manner detected by magnetic resonance imaging (MRI) [182] . Sodium caprate, a clinically used AE in the GI tract, when given as intracarotid infusion produced reversible, dose-related BBB opening for mannitol in rats [213] (Table 5) . However, high doses were toxic and caused severe brain edema and cardio-respiratory failure [213] .
The phospholipid LPA, found in animal sera used for cell cultures or released in high amount during subarachnoid haemorrhage, causes a rapid, reversible and dose-dependent decrease in TEER in brain endothelial cells [163, 245] . The barrier weakening was accompanied by redistribution of occludin, claudin-5 and ZO-1 indicating that TJ proteins are directly affected by LPA-treatment [245] .
The anionic surfactant SDS, widely used as solubilizer and stabilizer in pharmaceutical preparations, and a known AE, elicited an extensive, dosedependent and reversible BBB opening in rats [214] . Intracarotid infusion of SDS caused Evans blue extravasation, and a significant increase in γ-aminoisobutyric acid transport to brain. Part of the effect is hypothesized to be mediated by TJ modulation [214] . The ionic surfactant bile salts, effective as AE in the GI tract also induce reversible BBB opening. Sodium dehydrocholate infusion to the carotid artery of rats disrupted the BBB for fluorescein and Evans blue in a concentration-dependent manner [215, 216] . Sodium deoxycholate and taurochenodeoxycholate had the same effect when tested using in situ rat brain perfusion [217] . A modified bile salt, sodium dihydroxy-oxo-cholanate, enhanced BBB permeability for quinine, morphine and pentobarbital in rats, but its action on brain endothelial TJs is unspecified [218] . Because dehydrocholate and deoxycholate are strong detergents at high doses, and lytic action on endothelial cell membranes can be observed with the development of EEG changes and epileptiform activity [217, 246, 247] , their possible clinical application is limited.
The negative surface charge of the luminal endothelial membrane of brain vessels contributes to the barrier phenotype and cationic molecules show better BBB permeability (for review see [66] ). Intracarotid infusion of polycations protamine, poly-L-lysine and poly-L-arginine in rats resulted in permeability increase for albumin [219] . In a rat brain perfusion model protamine decreased the negative luminal surface charge in brain vessels and increased the extravasation of HRP by opening endothelial TJs [167] . The cationic polymer chitosan applied in microemulsion could improve nobiletin transport to brain in mice when given intravenously [220] , although the mode of action or specific effects on TJs have not been investigated.
Native α-CD-and β-CD-treatment causes a rapid increase in sucrose permeability of brain endothelial monolayers in parallel with their ability to extract phospholipids and cholesterol from the cell membranes [172] . Hydroxypropyl-γ-CD and γ-CD at high concentration increased doxorubicin transport across brain endothelial monolayers parallelly with the loss of BBB integrity and decreased junctional staining of occludin [173] . Rame-β-CD and chrisme-β-CD were also able to enhance doxorubicin transport in the same in vitro BBB model (Table 5) , and this effect correlated to the cholesterol extracting capacity of β-CDs, which may modulate TJs and the activity of efflux pumps in the brain endothelial cell membranes [221] .
While basal NO production is necessary for the BBB integrity, excessive NO release either by inducible NO synthase or by NO donors leads to increased permeability in BBB models [66] . NO donor molecule SNAP enhanced the BBB sucrose permeability about 5-fold in all forebrain regions using an in situ rodent brain perfusion method [222] . Intracarotid infusion of diethylammonium (Z)-1-(N,N-diethylamino)diazen-1-ium 1,2-diolate (DEA-NONOate) and (Z)-1-[N-(2-aminopropyl)-N-(2-ammonio propyl)amino]diazen-1-ium 1,2-diolate (PAPA-NONOate), short-acting NO donors, in RG2 tumour bearing rats led to increased transport of γ-aminoisobutyric acid to the tumour tissue [174] (Table 5 ). The effect of DEA-NONOate and PAPA-NONOate on brain tumour vessel permeability was mediated by calcium-activated potassium channels [174] (Table 4) .
Osmotic stress induced by mannitol or arabinose causes a rapid and reversible decrease in TEER, and increases permeability for paracellular markers sucrose and inulin through brain endothelial monolayers [66] , and in animal models (for review see [248] ). After intracarotid infusion of hyperosmotic arabinose dilatation of junctional clefts and changes in the localization and expression of TJ proteins occludin, claudin-5, JAM-1 and ZO-1 were observed in rats [224] . Src kinase mediated phosphorylation of AJ protein β-catenin may play a role in the mechanism of mannitol-induced TJ opening [175] . Ongoing multicenter clinical studies suggest that BBB disruption by intraarterial hyperosmotic mannitol can enhance the penetration of anticancer drugs and prolong survival in patients with malignant brain tumours [226] (Table 5 ). Despite successful application in some centers, the method has not been widely spread, because the procedure is difficult, invasive, and posttreatment neurotoxicity may develop.
Erdlenbruch et al. demonstrated, that the short chain alkylglycerol, 1-O-pentylglycerol, given to the carotid artery could rapidly and reversibly enhance the ipsilateral brain penetration of antineoplastic agents cisplatin and methotrexate and the antibiotics vancomycin and gentamycin in rats [249] . It also enhanced the delivery of erucylphosphocholine and methotrexate to rat C6 and RG2 implanted tumours [227, 228, 249, 250] . 1-O-pentylglycerol induced the extravasation of fluorescein, albumin and methotrexate in the ipsilateral brain and to the tumour by enhancing paracellular permeability of TJs [228] . The effect of 1-O-pentylglycerol was lower than that of hyperosmotic mannitol, and much higher than the effect of bradykinin, but in contrast to mannitol it did not enhance BBB permeability in the contralateral brain hemisphere or the cerebellum and brain stem [227] . The effect and duration of alkylglycerol-induced BBB-opening was more rapid and localized to the site of injection, with less in vivo toxicity [227] , offering a new and safer alternative of BBB disruption by hyperosmotic mannitol.
There are a growing number of papers describing experimental BBB opening by high intensity focused ultrasound (for review see [251] ). Low frequency MRI-guided ultrasound bursts could induce local, reversible disruption of BBB in rabbits [229] and increase the brain delivery of dopamine D4 receptor antibody, and a humanized anti-human epidermal growth factor receptor 2 monoclonal antibody, Herceptin, in mice [230, 231] , and doxorubicin in rats [232] (Table 5 ). The method is not specific to TJs, the mechanisms of transport of molecules by sonication can involve transcytosis, endothelial fenestration and channel formation, partial opening of TJs and free passage through injured endothelium [252] . If the method will be proved safe and effective in more experimental models, MRI-guided focused ultrasound may have a great potential to treat CNS malignancies [226] .
Although the 0.02 m 2 surface area of the blood-cerebrospinal fluid barrier created by the choroid plexus is negligible compared to the surface area of the BBB, it plays an important role in the regulation of drug transport and metabolism in the CNS [253, 254] . Blood vessels in the choroid plexus are leaky, and the barrier is formed by epithelial cells expressing TJ proteins occludin, claudin-1, -2, -5, -11, ZO-1 [255, 256] . Modulation of TJ permeability in choroid plexus epithelium and at the BBB shows similarities. The barrier permeability is increased by cyclic AMP [257] , and decreased by phorbol esterinduced activation of PKC both in vitro and in vivo [255, 258, 259] . The PKC-mediated permeabilization of epithelial cells is accompanied by dephosphorylation and reduced immunostaining of occludin, downregulation of claudin-2, decreased immunoreactivity for claudin-2, -5, cadherin and β-catenin [255, 258] . Modulation of TJs at the level of the choroid plexus might provide an additional route for drug delivery to the CNS.
Concluding remarks
In contrast to strategies targeting transepithelial/transendothelial pathways, modulators acting on TJs could enhance paracellular permeability of biological barriers for a large number and variety of drugs, including hydrophylic compounds, biopharmaceuticals, like peptides, proteins, nucleic acids, and viral vectors without the need to modify the drugs. The concept is proven by the clinical application of several AEs, like sodium caprate, cyclodextrins or oleic acid, which act, at least partly, through modification of epithelial tight junctions. Because of the low selectivity and relatively high toxicity of AEs there is a need for new TJ modulators.
Intense research in several laboratories to develop safe and effective TJ modulators will result in increasing number of new peptides specific for unique TJ proteins with better organ or region selectivity and lower toxicity in the near future. For example, the selectivity of C-CPE peptide targeting claudin-4 and acting in the jejunum, but not in colon, seems to be promising [117] . Targeting claudin-5, or claudin-1 could lead to TJ modulators selective for the BBB or for the skin.
Beside peptides, antibodies, antibody fragments and small interfering nucleic acids specific for TJ proteins could also be potential modulators of paracellular permeability. While signalling pathways regulating TJs look promising targets of chemical compound modulators, like kinase inhibitors, they are far from being clinically applicable. The organ or tissue selectivity and the safety of these molecules have to be first proven.
Opening of TJs for a drug molecule might result in the enhanced transport of other molecules, xenobiotics or pathogens across the protective barriers of the GI tract, the BBB or the airways. TJs and their components play a fundamental role in morphogenesis and cell polarity. Safety assessment of TJ modulators should include careful testing and analysis for global adverse drug reactions, enhanced sensitivity for bacterial or viral infections, and long-term carcinogenic or teratogenic effects.
Some of the new TJ modulators have already entered clinical trials. AT1001 (Table 2) , a TJ modulator to decrease intestinal hyperpermeability, has been tested for safety and efficacy to treat celiac disease [260] . The effect of the permeability enhancer PN-159 is being examined in Phase II studies on nasal insulin and peptide YY administration to control type 2 diabetes and induce weight loss in obesity, respectively [261] .
As a conclusion, the number of TJ modulators with a potential to be used in drug delivery is expected to greatly increase in the near future and provide an unprecedented selectivity for various barriers, as well as better efficacy and safety.
